The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
Andrew J. Armstrong
Honoraria - Pfizer
Research Funding - Pfizer
Tong Shen
No relevant relationships to disclose
Susan Halabi
No relevant relationships to disclose
Gabor Kemeny
No relevant relationships to disclose
Rhonda Lynn Bitting
No relevant relationships to disclose
Patricia Kartcheske
No relevant relationships to disclose
Elizabeth Embree
No relevant relationships to disclose
Karla Morris
No relevant relationships to disclose
Carolyn Winters
No relevant relationships to disclose
Tracy Jaffe
No relevant relationships to disclose
Mark T. Fleming
No relevant relationships to disclose
Daniel J. George
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer